Initial Testing (Stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

BACKGROUND: Quisinostat (JNJ-26481585) is a second generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards class I and II HDACs. Quisinostat was selected for clinical development as it showed prolonged pharmacodynamic effects in vivo and demonstra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Carol, Hernan, Gorlick, Richard, Kolb, E. Anders, Morton, Christopher L., Manesh, Donya Moradi, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Wozniak, Amy, Hickson, Ian, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225045/
https://ncbi.nlm.nih.gov/pubmed/24038993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24724
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados